GAIA BioMedicine is a biopharmaceutical company that specializes in innovative cell therapies and immunotherapies for treating solid tumors.
GAIA BioMedicine has raised $11.9M in total funding. The most recent round was Series B. The last funding was announced in September 2021.
GAIA BioMedicine's investors include SBI Investment, Osaka University Venture Capital, CEJ Capital, Hisamitsu Pharmaceutical.
GAIA BioMedicine is headquartered in Fukuoka, Japan.
GAIA BioMedicine is a biopharmaceutical company that specializes in innovative cell therapies and immunotherapies for treating solid tumors.
GAIA BioMedicine is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"GAIA BioMedicine — Funding & Investors." VCBacked, September 21, 2021, https://www.vcbacked.co/company/gaia-biomedicine. Accessed September 30, 2026.
VCBacked. (2021). GAIA BioMedicine — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/gaia-biomedicine
{{cite web |title=GAIA BioMedicine — Funding & Investors |url=https://www.vcbacked.co/company/gaia-biomedicine |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated